SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-032169
Filing Date
2024-08-14
Accepted
2024-08-14 16:05:54
Documents
15
Period of Report
2024-08-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44864
2 ex3-1.htm EX-3.1 14281
3 ex10-1.htm EX-10.1 27474
  Complete submission text file 0001493152-24-032169.txt   269834

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tnfa-20240808.xsd EX-101.SCH 3003
5 XBRL LABEL FILE tnfa-20240808_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE tnfa-20240808_pre.xml EX-101.PRE 22351
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3814
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 241207540
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)